Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

162 281

Changes in operating assets and liabilities:

Other assets 66 105

Accounts payable and accrued liabilities (1,557) 1,072

Deferred rent 1,452 1,443

Net cash used in operating activities (37,651) (32,105)

Investing activities:

Purchases of property and equipment (9,571) (8,586)

Purchases of short-term investments (14,899) (63,386)

Maturities of short-term investments 39,898 58,348

Restricted cash - (1,901)

Net cash provided by (used in) investing

activities 15,428 (15,525)

Financing activities:

Proceeds from debt 6,884 7,563

Payments on debt (6,092) (3,113)

Issuance of common stock and warrants 33,546 45,369

Repurchase of restricted common stock (2) (5)

Net cash provided by financing activities 34,336 49,814

Net increase in cash and cash equivalents 12,113 2,184

Cash and cash equivalents at beginning

of period 14,249 12,065

Cash and cash equivalents at end of period $26,362 $14,249

Supplemental disclosures of cash flow

information:

Cash paid for interest $1,363 $703

Supplemental non-cash activities:

Capitalized interest recorded as property,

plant and equipment $404 $91

Accrued asset acquisitions $(1,670) $1,819

Leasehold improvements acquired
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email: